Buddy Creech

Vials with medication and syringe on blue methacrylate table. Horizontal composition. Top elevated view.

Investigational vaccine to be tested against COVID-19 variant

Vanderbilt University Medical Center is participating in a national phase 1 clinical trial in healthy adults of an investigational vaccine against the B.1.351 variant of the COVID-19 virus that was first identified in South Africa.

Monroe Carell Jr. Children’s Hospital at Vanderbilt selected as trial site for pediatric COVID-19 vaccine

Monroe Carell Jr. Children’s Hospital at Vanderbilt is set to begin a phase 2/3 clinical trial to study the safety and efficacy of the Moderna COVID-19 vaccine in children.

The “orange team,” led by Buddy Creech, MD, director of the Vanderbilt Vaccine Research Program, assembles in the old Clinical Research Center space in Medical Center North on the first day of the phase 3 Moderna vaccine study this summer.

Coronavirus ‘crusaders’ spur VUMC research achievements

The development of the vaccines, monoclonal antibodies and antiviral drugs that ultimately will defeat COVID-19 wouldn’t have been possible had it not been for the unflagging and selfless efforts of a global army of research nurses, laboratory personnel, recruiters and other staff.

VUMC begins study of second COVID-19 vaccine

Vanderbilt University Medical Center has begun recruiting up to 250 participants for a Phase 3 clinical trial testing an investigational COVID-19 vaccine candidate developed by the Janssen Pharmaceutical Companies of Johnson & Johnson.

COVID treatment studied by VUMC gains FDA approval

Researchers at Vanderbilt University Medical Center played a key role in the development of remdesivir, the first drug approved by the U.S. Food and Drug Administration for the treatment of COVID-19.

Vanderbilt University Medical Center to recruit up to 1,000 volunteers for COVID-19 vaccine Trial

In late July, Vanderbilt University Medical Center will begin recruiting up to 1,000 volunteers in a late-stage study of an experimental COVID-19 vaccine developed by Moderna Inc. in collaboration with the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health.

1 2 3 4